NO940180L - Anvendelse av IGF-I - Google Patents

Anvendelse av IGF-I

Info

Publication number
NO940180L
NO940180L NO940180A NO940180A NO940180L NO 940180 L NO940180 L NO 940180L NO 940180 A NO940180 A NO 940180A NO 940180 A NO940180 A NO 940180A NO 940180 L NO940180 L NO 940180L
Authority
NO
Norway
Prior art keywords
igf
treatment
type
diabetes mellitus
drug
Prior art date
Application number
NO940180A
Other languages
English (en)
Other versions
NO940180D0 (no
Inventor
David B Dunger
Martin O Savage
Peter H Soenksen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO940180D0 publication Critical patent/NO940180D0/no
Publication of NO940180L publication Critical patent/NO940180L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anvendelse av IGF-I til frem- stilling av et medikament for behand- ling av type l diabetes mellitus. Medikamentet omfatter en subkutan dose som ikke er høyere enn den nødvendige for å oppnå et IGF-I-serumnivå karak- teristisk for friske individer, dvs. en fysiologisk erstatning for serum-IGF-I. Denne behandling vil være spesielt verdifull for behandling av barn eller ungdom med type l diabetes mellitus, og kan føre til forbedringer i deres pubertetsvekst.
NO940180A 1992-05-19 1994-01-18 Anvendelse av IGF-I NO940180L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1

Publications (2)

Publication Number Publication Date
NO940180D0 NO940180D0 (no) 1994-01-18
NO940180L true NO940180L (no) 1994-01-18

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940180A NO940180L (no) 1992-05-19 1994-01-18 Anvendelse av IGF-I

Country Status (11)

Country Link
US (1) US5466670A (no)
EP (1) EP0613376B1 (no)
JP (1) JPH06509361A (no)
AT (1) ATE207758T1 (no)
AU (1) AU669894B2 (no)
CA (1) CA2112358A1 (no)
DE (1) DE69331045T2 (no)
NO (1) NO940180L (no)
NZ (1) NZ252359A (no)
SE (1) SE9201573D0 (no)
WO (1) WO1993023071A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DE60005806T2 (de) 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
US6984405B1 (en) 2000-12-15 2006-01-10 Naturalendo Tech Co., Ltd. Compositions for inducing secretion of insulin-like growth factor-1
NZ526672A (en) * 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
CN101022820A (zh) 2004-08-30 2007-08-22 特西卡股份有限公司 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置
EP2763692A2 (en) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (en) * 1983-04-25 1993-09-29 Chiron Corporation Hybrid dna synthesis of mature insulin-like growth factors
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
DE69331045D1 (de) 2001-12-06
JPH06509361A (ja) 1994-10-20
NO940180D0 (no) 1994-01-18
ATE207758T1 (de) 2001-11-15
US5466670A (en) 1995-11-14
NZ252359A (en) 1997-05-26
EP0613376A1 (en) 1994-09-07
EP0613376B1 (en) 2001-10-31
AU669894B2 (en) 1996-06-27
WO1993023071A1 (en) 1993-11-25
SE9201573D0 (sv) 1992-05-19
AU4098893A (en) 1993-12-13
DE69331045T2 (de) 2002-03-21
CA2112358A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
NO940180L (no) Anvendelse av IGF-I
MX9701916A (es) Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la superficie.
TR200100079T2 (tr) Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
ATE82507T1 (de) Medizinische verwendung.
IT8323559A0 (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
ES8507567A1 (es) Metodo para estabilizar un concentrado de gamma globulina
WO1997040072A3 (en) Adam proteins and uses thereof
ATE86488T1 (de) Verwendung von minoxidil zur wundheilung.
ATE93730T1 (de) Methode zur erhoehung des wachstums des brustzellgewebes.
DK0914148T3 (da) Behandling af partielt væksthormonoverfølsomhedssyndrom
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
AU6102801A (en) Method of preventing or treating diabetes
EP0321094A3 (en) Treatment of factor viii inhibitors
李祖谟 235 CASES OF FROZEN SHOULDERTREATED BY MANIPULATIONANDMASSAGE
朱宝国 et al. A REPORT ON THE USE OF PULVIS RESINAE IN THE TREATMENT OF THROMBOANGIITIS OBLITERANS
Holst et al. Diurnal profile of pancreatic polypeptide and gut glucagon in human morbid obesity
Greene et al. The effect of age on ranitidine pharmacokinetics.
Pittman Why I love private practice.
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
IT8723080A0 (it) Componente d'arredamento, in particolare del tipo poltrona o simile.
TH16764A (th) การรักษาโรคเบาหวานโดยการให้ ไมโอ-ไอโนซิทอล
IT8821902A0 (it) Componente d'arredamento imbottito, in particolare del tipo divano, poltrona o simile
HUT45394A (en) Face-pack containing natrium-carboxi-methil-amilopectin